| Name | ZL006 |
| Description | ZL006 is an effective inhibitor of nNOS/PSD-95 interaction. ZL006 also inhibits NMDA receptor-mediated NO synthesis. |
| In vitro | ZL006 growth inhibition of BCECs is not found at a low concentration of 0.001, 0.01, 0.1, 1, and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is obviously enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs [1][2]. |
| In vivo | T7-P-LPs/ZL006 displays a significant enhance in drug accumulation in the brain tissue due to its better brain targeting delivery compared with P-LPs/ZL006 and free ZL006. P-LPs/ZL006 and T7-P-LPs/ZL006 show a significant decrease in drug accumulation in the liver and kidney compared with free ZL006 [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 29 mg/mL (88.37 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.09 mM), Sonication is recommended.
|
| Keywords | ZL-006 | ZL006 | ZL 006 | NMDA | Ionotropic glutamate receptors | Inhibitor | inhibit | iGluR |
| Inhibitors Related | Urethane | Decanoic Acid | N-Methylsarcosine | L-Glutamic acid | N,N-Dimethylglycine hydrochloride | L-Phenylalanine | glycine | Halothane | Indole-2-carboxylic acid | L-Glutamic acid monosodium salt | Memantine | Memantine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Neuroprotective Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library |